Compare prescribed tafamidis 61 mg costs with Korean NHI coverage, special-case registration and full drug payment. Plan 2026 annual payments, ceiling relief, confirmed support and a five-year repeated budget.
Assumes a prescribed 61 mg capsule once daily. Public reference KRW 100,000, effective March 1, 2025; checked 2026-11-02.
Your specialist confirms eligibility, diagnosis and treatment duration. Enter a separate provider quote for full drug cost.
Coverage or registration remains unknown. The figures below assume each path’s conditions apply; your actual applicable path is not established.
KRW 1,730,000
KRW 1,730,000
KRW 36,500,000
Monthly reserves do not represent actual monthly bills. Ceiling relief may include direct settlement and later refunds, so it is not a cash-refund quote. Five years repeats the same price, days and 2026 rules five times; it does not forecast treatment or coverage.
ATTR-CM is transthyretin amyloid cardiomyopathy, a disease involving amyloid deposits in the heart.
Vyndamax contains tafamidis, and this calculator organizes household costs for a specialist-prescribed 61 mg capsule once daily.
It does not decide whether to start, combine, change or stop treatment, or how long treatment should continue.
This page uses South Korean National Health Insurance rules for care within calendar year 2026.
The MFDS product page checked November 2, 2026 lists product code 648903510 and a public reference price of KRW 100,000, effective March 1, 2025.
A public reference is not a provider’s actual non-covered quote or a confidential risk-sharing agreement price.
Assumes both drug coverage and applicable special-case registration; the covered drug share is 10%.
Assumes drug coverage without the special rate; replace the 30% pharmacy reference with the actual confirmed percentage.
Assumes the patient pays the entire drug quote, such as outside reimbursement criteria; that drug payment is excluded from the ceiling.
Drug reimbursement and special-case registration are separate questions.
Missing registration alone does not automatically mean a 100% drug charge, and a hospital not yet stocking the product does not itself establish a non-covered billing classification.
Ask separately about supply, the prescription route, benefit criteria and your patient share.
Unknown evidence leaves all results conditional; a star only identifies the path matching the statuses you entered, not an approval by this website.
HIRA Notice No. 2026-69, effective April 1, 2026, distinguishes hereditary and wild-type pathways for confirmed ATTR-CM in adults aged 18 or older.
These are discussion checkpoints rather than an invitation to interpret imaging or diagnose yourself.
Response assessment is required before treatment and every 12 months afterward.
Stopping criteria include the specified exclusions, progression to NYHA IV, an absolute wall-thickness increase of at least 2 mm, or an absolute LVEF decrease of at least 5 percentage points compared with the preceding assessment.
Notice 2026-69 does not reimburse concurrent use with vutrisiran and requires a heart-related specialist prescription and objective documentation.
Your treating team interprets these criteria; never interrupt treatment because of a calculator result.
Enter 0–365 prescribed days falling between January 1 and December 31, 2026; the model assumes one prescribed 61 mg capsule per day and does not recommend extending treatment.
Keep the covered unit price separate from the full-cost provider quote; the default full-cost price merely repeats the public reference and must be replaced when an actual quote is available.
Enter the annual patient copay for related covered visits and tests, not the gross medical bill; the same care amount is held constant in all three comparisons and must not duplicate the drug cost.
Enter eligible medical spending from quotes or receipts; transport, ordinary caregiver charges and lost earnings do not belong in the medical tax-credit input.
A twelve-month course starting in November crosses two ceiling years and must not use one annual ceiling for the entire course.
Recalculate the next calendar year using its own prices and rules.
Zero default care or support amounts mean no extra amounts were entered, not that treatment is universally free of examination charges.
The ceiling under National Health Insurance Act Article 44 and Enforcement Decree Article 19 applies per patient and calendar year.
Do not combine relatives’ copays or include non-covered charges, full drug payments, selective benefits or other excluded charges in eligible spending.
Choose the income decile determined by NHIS premiums rather than inferring it from salary alone.
Additional relief = max(B + N − C, 0) − max(B − C, 0)
B is this patient’s other eligible copay in 2026, N is this plan’s eligible drug share plus the entered covered care copay, and C is the annual ceiling.
Full drug charges are excluded from N, although separately entered covered care may still count.
The second term prevents an existing refund from being attributed to this new drug budget.
| Premium decile | General ceiling | Nursing hospital over 120 days |
|---|---|---|
| 1 | 900,000 | 1,430,000 |
| 2–3 | 1,120,000 | 1,810,000 |
| 4–5 | 1,730,000 | 2,450,000 |
| 6–7 | 3,260,000 | 4,040,000 |
| 8 | 4,460,000 | 5,800,000 |
| 9 | 5,360,000 | 6,980,000 |
| 10 | 8,430,000 | 10,960,000 |
The 120-day distinction concerns nursing-hospital admissions, not capsule days.
Relief can involve provider settlement and later refunds; amounts already settled are not paid again, so the result is not a promise of a new cash refund.
Final premium classification, excluded bills and deductions for insurance arrears can change the settlement.
At decile 10, the general ceiling is KRW 8,430,000, so the 10% drug share generates no relief, while the ordinary path generates KRW 2,520,000 relief.
Equal net costs at a lower ceiling do not mean equal upfront payments or cash needed while waiting for settlement.
Turn off ceiling relief to examine a budget before assuming it applies.
Vyndamax appears in a published full-payment patient support contact list for risk-sharing drugs, but this does not establish a universal refund rate or your eligibility.
Confirm the patient, prescription, period and payable amount, and enter a distinct amount for each path.
Support must be a confirmed payment against cost remaining after NHIS settlement, without overlapping ceiling relief.
The model applies 15% to qualifying medical expenses above 3% of the claiming employee’s gross salary.
The ordinary eligible-base cap is KRW 7,000,000; protected categories include the employee themself, a person aged 65 or older at year-end, disability and applicable verified statutory special cases.
Confirm the exception for this patient before selecting it.
Other ordinary net expenses use the 3% threshold first, and any unused threshold reduces protected expenses.
The result is total credit with this plan minus the existing credit, after removing ceiling relief, support and indemnity reimbursement.
Already reimbursed expenses must not be claimed again.
For salary KRW 50,000,000, no other expenses and net medical cost KRW 1,730,000, the threshold is KRW 1,500,000 and the illustrative additional national credit is KRW 230,000 × 15% = KRW 34,500.
This is not a cash benefit for a patient without employee tax liability.
Actual payer eligibility, tax liability, other credits, the standard-credit choice and later refund corrections require review; local income tax is not included.
Cost inputs are processed in your browser, and the budget needs no patient name or medical-record number.
Recalculate when the quote or registration period changes rather than reusing an old result.
This model covers only prescribed Vyndamax 61 mg.
Vyndaqel 20 mg requires separate confirmation of formulation, labeled ingredient, indication and reimbursement; do not substitute products or convert capsule counts yourself.
Other ATTR treatments, transplantation costs and health effects of treatment delays are outside the calculation.
No; the provider must confirm diagnostic evidence, adult age, the hereditary or wild-type pathway, exclusions, specialist prescription and required documentation.
Not necessarily; covered treatment may use an ordinary copay, while outside-criteria drug payment is a separate question.
No; the designated institution and NHIS determine your actual registration code and validity, and the rate does not extend to all heart disease.
No; full drug charges and non-covered medical bills are excluded from the eligible ceiling amount in this model.
Both may exceed the same annual ceiling; the initial amounts payable and cash needed before settlement can still differ substantially.
No; enter only patient-specific confirmed payments, excluding any amount already counted as ceiling relief.
The additional national credit is illustrative; actual liability, other credits and payer eligibility affect what can be used, so it is not deducted from the payment budget.
No; it repeats current annual inputs and 2026 assumptions for arithmetic comparison, and treatment and policy must be reviewed independently.
Verified November 2, 2026, using the same official evidence as the Korean version.
Direct law API checks include National Health Insurance Act MST285273 Article 44 (October 8, 2026), Decree MST289701 Article 19 (October 1, 2026), and special-case Notice 2026-162 (July 31, 2026).
Income Tax Act MST280405 Article 59-4 itself took effect January 1, 2026; Decree MST290841 Article 118-5 uses October 1, 2026.
Drug criteria are from HIRA Notice 2026-69, annex pages 16–17, effective April 1, 2026; recheck later product-specific amendments and actual provider conditions.
Ask your provider about the actual price and coverage, confirm registration dates, and check the NHIS decile and payment-account details.
Recheck annual price updates, criteria, ceilings, support overlap and tax rules whenever the budget is reused.